

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: )  
)  
C. Jane ROBINSON et al. ) Group Art Unit: To Be Assigned  
)  
Serial No.: To Be Assigned ) Examiner: To Be Assigned  
)  
Filed: Herewith )  
)  
For: Antithrombin III for Disorders )  
Caused by Angiogenesis )

J1011 U.S. PTO  
10/046278  
01/16/02

Commissioner for Patents and Trademarks  
Washington, DC 20231

Sir:

**INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)**

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants bring to the attention of the Examiner the documents listed on the attached PTO 1449. This Information Disclosure Statement is being filed with the above-referenced application and therefore before the mailing date of a first Office Action on the merits for the above-referenced application.

Copies of the listed documents are attached.

Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com

documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and Applicants determine that the cited documents do not constitute "prior art" under United States law, Applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such documents.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,  
GARRETT & DUNNER, L.L.P.

Dated: January 16, 2002

By: Carol P. Einaudi  
Carol P. Einaudi  
Reg. No. 32,220

LAW OFFICES  
FINNEGAN, HENDERSON,  
FARABOW, GARRETT,  
& DUNNER, L.L.P.  
1300 I STREET, N.W.  
WASHINGTON, D.C. 20005  
202-408-4000

INFORMATION DISCLOSURE CITATION

U.S. PTO  
 10/04/2001  
 01/16/02

Atty. Docket No. 06478.1463-00000	Serial No. To Be Assigned
Applicant C. Jane ROBINSON et al.	
Filing Date Herewith	Group: To Be Assigned

U.S. PATENT DOCUMENTS							
Examiner Initial*		Document Number	Issue Date	Name	Class	Sub Class	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS							
		Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
	Abdulkadir, S.A., et al., "Tissue Factor Expression and Angiogenesis in Human Prostate Carcinoma," <i>Human Pathology</i> , 31(4):443-447 (2000).
	Carmeliet, P., "Mechanisms of Angiogenesis and Arteriogenesis," <i>Nature Medicine</i> , 6(3):389-395 (2000).
	Romisch, J., et al., "Antithrombin III Isoform Proportion in Plasmas of Healthy Subjects, Septic Patients and at III Concentrates: A Novel Method of Quantification," Abstract, <i>Intens. Care Med.</i> 2000, 26(3):S303 (2000).
	O'Reilly, M.S., et al., "Antiangiogenic Activity of the Cleaved Conformation of the Serpin Antithrombin," <i>Science</i> , 285:1926-1928 (1999).
	Vacca, A., et al., "Antiangiogenesis is Produced by Nontoxic Doses of Vinblastine," <i>Blood</i> , 94(12):4143-4155 (1999).
	Witmer, M.R., et al., "Antithrombin III-β Associates more Readily than Antithrombin III-α with Uninjured and De-endothelialized Aortic Wall <i>In Vitro</i> and <i>In Vivo</i> ," <i>Arterioscler. Thromb.</i> , 11(3):530-539 (1991).

Examiner	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
Form PTO 1449	Patent and Trademark Office - U.S. Department of Commerce